No Data
CRISPR Therapeutics Q1 EPS $(1.58) Misses $(1.21) Estimate, Sales $865.00K Miss $6.50M Estimate
Earnings Flash (CRSP) CRISPR Therapeutics AG Posts Q1 Revenue $865,000
CRISPR Therapeutics | 10-Q: Quarterly report
Crispr Therapeutics: Initial CTX310 Phase 1 Clinical Data Demonstrates Dose-Dependent Decreases in TG and LDL >CRSP
CRISPR Therapeutics | 8-K: CRISPR Therapeutics Provides First Quarter 2025 Financial Results and
CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data From Phase 1 Clinical Trial of CTX310 Targeting ANGPTL3